RxDoctor Payments Data

Jamie Krusling, APRN

Nurse Practitioner · Crestview Hills, KYNPI 1649733510

Payments from drug & device makers

$5,276in general payments, 2019–2025

Across 224 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • SK Life Science, Inc.$914
  • Amneal Pharmaceuticals LLC$488
  • Jazz Pharmaceuticals Inc.$464
  • Livanova USA, Inc.$335
  • Lilly USA, LLC$165
  • plus $2K from 36 others

What the payments were for

  • Travel & lodging$1763%
  • Food & beverage$5,09997%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,276 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$33,570
Medicare patients
182
Services billed
1,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate50$68,673
Emgality PenGalcanezumab-Gnlm55$59,628
QuliptaAtogepant26$50,520
UbrelvyUbrogepant47$48,843
Aimovig AutoinjectorErenumab-Aooe31$39,914
Oxtellar XrOxcarbazepine18$34,475
XcopriCenobamate33$32,122
Trokendi XrTopiramate14$28,632
BriviactBrivaracetam20$21,257
Lacosamide88$17,618
Levetiracetam424$16,312
Topiramate ErTopiramate18$12,322
Carbamazepine ErCarbamazepine51$9,833
Memantine Hcl216$5,950
Clobazam15$5,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$1,115$99,36373 claims
PfizerNurtec Odt$142$68,67350 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr, Trokendi Xr$79$63,10732 claims
SK Life Science, Inc.Xcopri$914$32,12233 claims
UCB, Inc.Briviact$95$21,25720 claims
Upsher-smith Laboratories LLCTopiramate$16$1,19198 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Crestview Hills

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →